Key Highlights

  • AXGN shares are indicated up 19.83% at $44.89 in premarket, against a prior close of $37.46.
  • Q3 revenue was $75.8 million, up 26.2%, versus the roughly $73.2 million consensus.
  • Adjusted EPS was $0.21 against an expected $0.13.
  • 2026 revenue guidance rose to at least $290 million, above the roughly $283 million consensus.
  • Axogen will begin prostate market development in 2027 and hosts a prostate-focused call on November 9.

Q3 Beat and Raised Outlook Drive a Premarket Surge

Axogen (NASDAQ:AXGN) shares are indicated up 19.83% at $44.89 in premarket after third-quarter results topped expectations and management raised its 2026 outlook. Revenue of $75.8 million, up 26.2% from $60.1 million, beat the roughly $73.2 million consensus, and adjusted EPS of $0.21 beat the expected $0.13. The stock closed Tuesday at $37.46, down 1.47%.

Axogen, headquartered in Alachua, Florida, develops and commercializes surgical solutions for peripheral nerve repair and regeneration. Its portfolio includes the Avance Nerve Graft, a processed human nerve allograft that accounts for roughly 60% of revenue, along with Axoguard nerve connectors, protectors and caps, the Avive soft tissue matrix and the newly acquired NerveTape. The company sells mainly through a direct U.S. sales force under CEO Michael Dale.

Guidance Moves Above Consensus

Management now expects 2026 revenue of at least $290 million, up at least 29% and above the roughly $283 million consensus, including at least $7 million from the BioCircuit acquisition. Organic revenue is expected to be at least $283 million, up at least 26%. Gross margin is expected to be at least 73%, with positive free cash flow for the full year.

Payer Wins and Prostate Plans Extend the Growth Story

Axogen received positive coverage decisions from Elevance Health (NYSE:ELV) and Aetna, part of CVS Health (NYSE:CVS), bringing commercial payer coverage for Avance to about 96% of covered lives. Year-to-date revenue growth was broad-based across extremities, oral maxillofacial and head and neck, and breast, driven by account productivity gains of more than 20%.

Based on positive clinical study outcomes, Axogen will begin prostate market development in 2027 and hosts a prostate-focused investor call on November 9.

Cash Balance Jumps, but Gross Margin Slips

Axogen closed the BioCircuit acquisition on October 1 and ended September with $350.1 million in cash, restricted cash and investments, up from $113.4 million at the end of June after an upsized public offering with $225 million in net proceeds. Gross margin slipped to 74.8% from 76.6%.

Net income was $2.3 million, or $0.04 per share, and adjusted EBITDA rose to $13.4 million from $9.2 million. Axogen has a market cap of $2.20 billion, and the 52-week range runs from $17.14 to $52.91. The consensus target is about $53.